Recent Multiple Sclerosis Market Events Have Resulted in Treatment Algorithm …MarketWatch (press release)Patient profiles for the seven DMAs in late clinical development (alemtuzumab, BG-12, teriflunomide, laquinimod, PEG-Avonex, daclizumab, ocrelizu…
Biogen Idec: Q3 Clues To ValueSeeking AlphaIn addition Daclizumab HYP showed good Phase 2b trial results. Dexpramipexole for Lou Gehrig's (ALS) disease Phase III trial became fully enrolled recently. Third quarter (Q3) results released on October 2…
Promising new treatments on the horizonMS TrustDaclizumab, also known as Zenepax, is a monoclonal antibody already licensed for prevention of kidney transplant rejection. The SELECT trial tested subcutaneous (under the skin) injections of either placeb…
Daclizumab Shows Promise in Multiple Sclerosis TrialFamily Practice News Digital NetworkAMSTERDAM – Daclizumab reduced the rate of relapse and the rate of disability progression in patients with relapsing-remitting multiple sclerosis in a 1-year, pla…
Daclizumab Shows Promise in Multiple Sclerosis TrialInternal Medicine News Digital NetworkAMSTERDAM – Daclizumab reduced the rate of relapse and the rate of disability progression in patients with relapsing-remitting multiple sclerosis in a 1-year, p…
Proactive Investors USA & CanadaBiogen Idec (BIIB) Announces Quarterly ResultsLocalizedUSAIn addition to the marketed products, Biogen Idec has a number of product candidates in or near registrational stage development. It includes BG-12, Daclizumab, F…
Biogen Idec's CEO Discusses Q3 2011 Results – Earnings Call TranscriptSeeking AlphaAdditional news this quarter from our late-stage pipeline, including data presented at last week's ECTRIMS meeting for SELECT, the first of 2 registrational tria…
Biogen Idec Reports Third Quarter 2011 ResultsMarketWatch (press release)Therapies in Biogen Idec's MS franchise presented at the conference included TYSABRI, BG-12, FAMPYRA(R) (prolonged-release fampridine tablets), AVONEX, and daclizumab high-yie…
Promising Results for Daclizumab High-Yield in MSMedscapeOctober 27, 2011 (Amsterdam, the Netherlands) — Full results of the SELECT trial comparing 2 doses of daclizumab high-yield process (Biogen Iden/Abbott) with placebo confirm that both doses red…
Proactive Investors USA & CanadaBiotech Investing Lessons Learned: Diversify, Be PatientSeeking AlphaIn Biogen's case, results are for daclizumab for multiple sclerosis and for BG-12 for MS as well. Onyx's results are for regorafenib for metast…